Names Potentially Well Positioned to Beat Year-End Estimates
With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half....
687 Views
Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.9k Views
Nippon Shinyaku (4516 JP): Viltepso Concerns Deepen in 9MFY26, Guidance Marginally Revised
Nippon Shinyaku's revenue grew 5% in 9MFY26, driven by higher licensing fees and higher sales of ethical drugs. Viltepso face pressure in US. FY26...
204 Views
Kissei Pharma (4547 JP): 9MFY26 Stable, Guidance Reiterated, Linzagolix Japan Launch Awaited
Kissei Pharmaceutical sees 11% revenue growth in 9MFY26 driven by key products. Expects stable FY26 with focus on Linzagolix (for uterine...
179 Views
Nippon Shinyaku (4516 JP): Deramiocel Data Positive, Approval and Commercialization Next Big Trigger
Nippon Shinyaku and Capricor announce positive Phase 3 results for Deramiocel, with potential FDA approval and commercialization on the horizon....
584 Views